Lifevantage (LFVN) risk factors, FY2026 10-K

Lifevantage's FY2026 10-K, filed Aug 27, 2026, lists 55 risk factors in 4 groups. Against the prior year's 51: 5 new, 1 dropped, 10 substantially reworded.

Risk factors listed
554 groups
New this year
5vs 51 last year
Dropped
1since the prior 10-K
Substantially reworded
10of those kept
Section length
16k wordsItem 1A

What the changes say

  • Activist-stockholder disruption and AI adoption are newly highlighted risks this year.
  • Capital-raising constraints and international intellectual-property exposure receive expanded treatment.
  • The company dropped its specific tax, tariff, and trade-policy risk.
  • Class-action litigation detail increased, while potential equity dilution fell from 0.9 million to 0.3 million shares.

What changed since the prior 10-K

New

  • NewRisks Relating to Our Business and Industry

    of operations and financial condition. For example, in fiscal year 2024, we were engaged in a proxy contest with one of our stockholders, which was expensive and required significant time and attention by us, our board, and executive leadership team

    Stockholder activism, including proxy contests or board changes, could disrupt strategy, damage relationships, hinder hiring, and cause stock-price volatility.

  • NewRisks Relating to Our Company

    Our adoption, deployment, use or integration of artificial intelligence technologies may present operational, competitive, legal, regulatory, cybersecurity, privacy, reputational and other risks, and may not achieve the benefits we expect

    AI used in operations, marketing, consultant tools, forecasting, and compliance could generate flawed outputs or create legal, privacy, cybersecurity, and reputational problems.

  • NewRisks Relating to Our Company

    the costs of responding to the other risks and uncertainties described in this report

    Lifevantage may need additional capital for acquisitions, marketing, customer support, new products, market expansion, or licensing.

  • NewRisks Relating to Our Company

    financing capital expenditures and general and administrative expenses

    Equity or debt financing could dilute shareholders, rank ahead of common stock, or be constrained by the 2024 Credit Facility.

  • NewRisks Related to Regulatory, Compliance, and Legal Matters

    protections may not adequately protect our intellectual property. In addition, we could be required to expend significant resources to defend our rights to proprietary information and may not be successful in such defense

    Limited intellectual-property protection outside the United States, challenged patents, unavailable licenses, or copied products could weaken competitive protection.

Dropped

  • DroppedRisks Relating to Our Company

    economic dynamics that affect exchange rate fluctuations, it is difficult to predict future fluctuations and the effect these fluctuations may have upon future reported results or our overall financial condition

Reworded

  • 82% rewrittenRisks Relating to Our Business and Industry

    Actions of activist stockholders have, and could continue to, impact the pursuit of our business strategies, cause us to incur substantial costs, divert our management’s attention and resources, and adversely affect our business, results of operations, financial condition, and the trading price of our common stock

    The shown text is unchanged through the excerpt, so no substantive change is identifiable.

  • 70% rewrittenRisks Related to Regulatory, Compliance, and Legal Matters

    Our intellectual property rights are valuable, and any inability to protect them could reduce the value of our products and brand

    The shown text retains the March 2025 Protandim® Nrf2 Synergizer® patent-expiration example and existing protection measures; no substantive change is visible.

  • 63% rewrittenRisks Relating to Our Company

    A substantial portion of our business is conducted in foreign markets, exposing us to the risks of trade or foreign exchange restrictions, increased tariffs, foreign currency fluctuations, disruptions or conflicts with our third-party importers and similar risks associated with foreign operations

    The foreign-markets risk appears substantively unchanged, still covering tariffs, trade restrictions, foreign exchange, and third-party importer disruptions.

  • 57% rewrittenRisks Relating to Our Company

    We may require substantial additional funding, which may not be available to us on acceptable terms, or at all, and, if not available, may require us to delay, scale back, or cease our product development or growth plans

    The funding risk appears unchanged: cash and operating flows are expected to cover requirements for at least 12 months, but shortfalls could require capital.

  • 41% rewrittenRisks Related to Ownership of Our Common Stock

    We may become involved in legal proceedings that are expensive, time-consuming and, if adversely adjudicated or settled, could adversely affect our financial results

    The revision specifically adds class-action lawsuits, potentially large or indeterminate recoveries, and prolonged uncertainty about losses.

  • 34% rewrittenRisks Relating to Our Company

    We rely on our IT systems to manage numerous aspects of our business, and a disruption in these systems, including as a result of cybersecurity incidents, could adversely affect our business

    The revision removes the closing statement that IT disruption could harm competitive position, business, and operating results.

  • 31% rewrittenRisks Related to Ownership of Our Common Stock

    Additional shares that may be issued upon the exercise of currently outstanding options or upon future vesting of restricted stock units, would dilute the voting power of our currently outstanding common stock and could cause our stock price to decline

    Common shares increased from 12.4 million to 12.5 million, while target-level restricted stock units decreased from 0.9 million to 0.3 million.

  • 26% rewrittenRisks Related to Ownership of Our Common Stock

    Delaware law and provisions in our certificate of incorporation and amended and restated bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock

    The anti-takeover discussion is substantively unchanged in the excerpt, with formatting changes and continued emphasis on board-issued preferred stock.

  • 24% rewrittenRisks Relating to Our Business and Industry

    We primarily depend on a few products for a majority of our revenue

  • 21% rewrittenRisks Related to Ownership of Our Common Stock

    In addition, such macroeconomic conditions could impact our ability to access the public markets as and when appropriate or necessary to carry out our operations or our strategic goals. We cannot predict the ongoing extent, duration, or severity of these conditions, nor the extent to which we may be impacted

All 55 risk factors

Headings as the filing states them, in filing order.

Risks Relating to Our Business and Industry

  1. 01An inability to properly motivate and incentivize sales from our independent consultants could harm our business
  2. 02If we are unable to retain our existing customers and independent consultants or attract additional customers and independent consultants, our revenue will not increase and may decline
  3. 03Our independent consultants could fail to comply with applicable legal requirements or our policies and procedures, which could result in claims against us that could harm our business
  4. 04We may be adversely affected by changes to our independent consultant compensation plans
  5. 05We primarily depend on a few products for a majority of our revenue24% rewritten
  6. 06We are dependent upon third parties to manufacture our products
  7. 07High quality materials for our products may be difficult to obtain or expensive
  8. 08Disruptions to or significantly increased costs associated with transportation and other distribution channels for our products may adversely affect our margins and profitability
  9. 09We are subject to risks related to product recalls
  10. 10Our business is susceptible to product liability claims
  11. 11Many of the markets in which we compete for business, including the dietary supplement and personal care markets, are highly competitive. We may not be able to compete effectively, which may have a material adverse effect on our results of operations and financial condition
  12. 12Unfavorable publicity could materially harm our business
  13. 13Actions of activist stockholders have, and could continue to, impact the pursuit of our business strategies, cause us to incur substantial costs, divert our management’s attention and resources, and adversely affect our business, results of operations, financial condition, and the trading price of our common stock82% rewritten
  14. 14of operations and financial condition. For example, in fiscal year 2024, we were engaged in a proxy contest with one of our stockholders, which was expensive and required significant time and attention by us, our board, and executive leadership teamNew
  15. 15The loss of or inability to attract key personnel could negatively impact our business
  16. 16We may be held responsible for certain taxes or assessments and other obligations relating to the activities of our independent consultants, which could harm our financial condition and operating results
  17. 17We are subject to risks related to a Global Not For Resale Program

Risks Relating to Our Company

  1. 18Our adoption, deployment, use or integration of artificial intelligence technologies may present operational, competitive, legal, regulatory, cybersecurity, privacy, reputational and other risks, and may not achieve the benefits we expectNew
  2. 19We may not be successful in expanding our operations
  3. 20If we are able to expand our operations, including through acquisition of assets or businesses, we may experience difficulties in managing our future growth, which could adversely affect our business
  4. 21We may not succeed in growing our business in existing markets or opening new markets
  5. 22Inability of new products and technological innovations to gain market acceptance by customers and/or independent consultants could harm our business
  6. 23Our business could be negatively impacted if we fail to execute any product launch process due to increased pressure on our supply chain, information systems and management
  7. 24Our business may be harmed if we are unable to appropriately manage our inventory
  8. 25We rely on our IT systems to manage numerous aspects of our business, and a disruption in these systems, including as a result of cybersecurity incidents, could adversely affect our business34% rewritten
  9. 26In April 2024, we entered into a loan agreement, which we amended in September 2025, that provides for a revolving line of credit in an aggregate principal amount not to exceed $5.0 million (the “2024 Credit Facility”). As of June 30, 2026, there is no outstanding balance on the 2024 Credit Facility
  10. 27A substantial portion of our business is conducted in foreign markets, exposing us to the risks of trade or foreign exchange restrictions, increased tariffs, foreign currency fluctuations, disruptions or conflicts with our third-party importers and similar risks associated with foreign operations63% rewritten
  11. 28We may require substantial additional funding, which may not be available to us on acceptable terms, or at all, and, if not available, may require us to delay, scale back, or cease our product development or growth plans57% rewritten
  12. 29the costs of responding to the other risks and uncertainties described in this reportNew
  13. 30financing capital expenditures and general and administrative expensesNew

Risks Related to Regulatory, Compliance, and Legal Matters

  1. 31Our business is subject to strict government regulations
  2. 32enacted that restrict our ability to market or distribute dietary supplements or impose additional burdens or requirements on dietary supplement companies or require us to reformulate our products
  3. 33Regulations governing the production and marketing of our products could harm our business
  4. 34We are subject to the risk of investigatory and enforcement action
  5. 35Our direct selling program could be found to be not in compliance with current or newly adopted laws or regulations in one or more markets, which could prevent us from conducting our business in these markets and harm our financial condition and operating results
  6. 36Laws and regulations may prohibit or severely restrict direct selling and cause our revenue and profitability to decline, and regulators could adopt new regulations that negatively impact our business
  7. 37Our financial condition and results of operations may be adversely affected by international regulatory and business risks
  8. 38Our intellectual property rights are valuable, and any inability to protect them could reduce the value of our products and brand70% rewritten
  9. 39protections may not adequately protect our intellectual property. In addition, we could be required to expend significant resources to defend our rights to proprietary information and may not be successful in such defenseNew
  10. 40Third parties might claim that we infringe on their intellectual property rights

Risks Related to Ownership of Our Common Stock

  1. 41Our stock price may experience future volatility
  2. 42Substantial sales of shares of our common stock in the public market may impact the market price of our common stock
  3. 43We cannot guarantee that our share repurchase program will be utilized to the full value approved or that it will enhance long-term stockholder value. Repurchases we consummate could increase the volatility of the price of our common stock and could have a negative impact on our available cash balance
  4. 44Additional shares that may be issued upon the exercise of currently outstanding options or upon future vesting of restricted stock units, would dilute the voting power of our currently outstanding common stock and could cause our stock price to decline31% rewritten
  5. 45If we are unable to maintain compliance with Nasdaq requirements for continued listing, our common stock could be delisted from trading
  6. 46We are a “smaller reporting company” and may take advantage of certain scaled disclosures available to us. We cannot be certain if the reduced reporting requirements applicable to smaller reporting companies will make our common stock less attractive to investors
  7. 47Delaware law and provisions in our certificate of incorporation and amended and restated bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock26% rewritten
  8. 48We may become involved in legal proceedings that are expensive, time-consuming and, if adversely adjudicated or settled, could adversely affect our financial results41% rewritten
  9. 49If we fail to maintain proper and effective internal controls, our ability to produce accurate and timely financial statements could be impaired, which could result in sanctions or other penalties that would harm our business
  10. 50Government authorities may question our tax positions or transfer pricing policies or change their laws in a manner that could increase our effective tax rate or otherwise harm our business
  11. 51Economic, political, and other risks associated with our international operations could adversely affect our revenue and international growth prospects
  12. 52Unfavorable global economic conditions, including high inflation, tariffs, and other macroeconomic conditions or trends may have an adverse impact on our business, financial results, and prospects
  13. 53In addition, such macroeconomic conditions could impact our ability to access the public markets as and when appropriate or necessary to carry out our operations or our strategic goals. We cannot predict the ongoing extent, duration, or severity of these conditions, nor the extent to which we may be impacted21% rewritten
  14. 54We could be subject to securities class action litigation
  15. 55If securities or industry analysts cease publishing research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline

Other Lifevantage 10-Ks

  • FY2025 10-K risk factors
    51 risks

    The risk section is dominated by direct selling network vulnerabilities, regulatory scrutiny of marketing claims, and third-party manufacturing dependencies.

    Filed Sep 04, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.